# TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

> **NCT06455917** · PHASE2 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** TILs（Tumor Infiltrating Lymphocytes）

## Key facts

- **NCT ID:** NCT06455917
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455917, "TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06455917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*